* Esperion Therapeutics Inc says intends to initiate planned
CVOT in statin intolerant patients who are at high risk for CV
disease in Q4 of 2016
The post BRIEF-Esperion Therapeutics provides regulatory update for Bempedoic Acid appeared first on NASDAQ.